0A4Y Stock Chart & Stats
$0.26
>-$0.01(-2.01%)
At close: 4:00 PM EDT
$0.26
>-$0.01(-2.01%)
Day’s Range― - ―
52-Week Range$0.20 - $3.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)184.56K
Market Cap
$6.93M
Enterprise Value-$1.18
Total Cash (Recent Filing)$9.96M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding30,442,139
10 Day Avg. Volume506,109
30 Day Avg. Volume184,562
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.25Price Target Upside1534.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
Bulls Say, Bears Say
Bulls Say
Ampligen Patent ProtectionThe newly issued U.S. patent extends protection for a cancer combination involving Ampligen through 2039. This strengthens the company’s intellectual-property position and could support future partnering, clinical development, and commercial differentiation if efficacy and regulatory milestones are achieved.
Clinical Manufacturing ReadinessExpanding manufacturing capacity and transferring test methods directly support clinical supply for ongoing studies and a potential Phase 3 pancreatic-cancer trial. This improves execution readiness and gives the pipeline a more practical path toward advancing development over the next several quarters.
Low Current LeverageCurrent debt is modest relative to reported equity, so interest obligations are not the primary financial constraint on the business today. That comparatively light leverage provides some flexibility to direct capital toward clinical development, although continued losses still require careful financing management.
Bears Say
Minimal Revenue And Persistent LossesThe company remains dependent on an early-stage drug pipeline rather than established commercial revenue. Extremely small sales, negative gross profit, and sizable recurring losses indicate that the business has not yet demonstrated a self-funding operating model, leaving results highly dependent on development progress.
Sustained Cash BurnOperating activities continue to consume substantial cash, and free cash flow closely tracks the reported net loss. This persistent burn reduces the time available to reach clinical or commercial milestones and makes additional financing an ongoing requirement for maintaining research and trial operations.
Equity Financing And Dilution DependenceUsing large share issuances to extinguish debt and fund operations can reduce financial obligations, but it transfers the burden to existing shareholders through dilution. Repeated equity-based financing also signals that internal cash generation is insufficient to fund the pipeline independently over the medium term.
AIM ImmunoTech News
0A4Y FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest share price was $0.20 and its highest was $3.32 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $6.93M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 17, 2027 which is in 344 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 10, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.26.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech does not currently pay dividends.
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 30,442,139 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -6.429%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in GB:0A4Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
0A4Y Stock 12 Month Forecast
Average Price Target
$4.25
▲(1534.62% Upside)